- Stronger Yuan Needed for Global Rebalancing: IMF Chief
- Washington Not Trying to Contain China: Obama
- Japan Third Quarter GDP Jumps; 2010 Growth May Slow
- Quiz: How Much Do You Know About Green?
- Citi Rejects Terra Firma's Latest Bid to Save EMI: Report
- Analysis: APEC Nations Back Face-Saving Climate Plan
- BlackRock: Central Banks To Be Net Buyers of Gold
- GM to Start Repaying $6.7 Billion US Government Loan
- Canon to Buy Dutch Oce in $2.2 Billion Deal
- Warren Buffett to CNBC: 'I Haven't Bought American Express In Years'
- CNBC Video: Warren Buffett & Bill Gates - Keeping American Great
- U.S. Stocks Rally for the Second Straight Week
- Dollar is Not Plunging—So 'Calm Down': Market Strategist
- Strategists Say Markets Have More Upside — But How Much?
- Hirschhorn: Risk-Averse Traders
- Roginsky: A Funny Thing Happened on the Way to Financial Reform
- This Year's Biggest Thanksgiving Leftover: Cash
- TV Series Inks Unique Deal For Fight
- Obama prods China to accept ‘universal rights’
- Airbus parent EADS reports Q3 loss on weak dollar
- Calif. man set for hearing in wine warehouse fire
- Census: Small US cities lose luster in downturn
- Dakotas might see record sunflower yields
- Emirates chief: Boeing, Airbus orders possible
- Remittances of Filipinos abroad up 8.6 percent
- Source: GM to begin repaying aid by year-end
- MasterCard holiday gift campaign pairs with Amazon
Text Size 
CAMBRIDGE, Mass. - Drug developer Ariad Pharmaceuticals Inc. said Thursday its third-quarter loss widened slightly on overall costs as it continues developing potential cancer treatments.
The company reported a loss of $20.8 million, or 21 cents per share, compared with a loss of $20 million, or 29 cents per share, a year earlier. The company had fewer shares outstanding in the same period a year ago.
Revenue rose 40 percent, to $2.2 million from $1.5 million.
Analysts polled by Thomson Financial expected a loss of 18 cents per share on revenue of about $2.6 million.
The company's lead product candidates include the cancer treatment ridaforolimus, which is being developed in a partnership with Merck & Co.
Shares of Ariad closed at $1.98 Thursday.
Print
Email
- Where, what, how.
- Warren Buffett and Bill Gates spoke to Columbia students, and Buffett made the students a startling offer.
- For the chief of cable company Comcast, growth has been about making deals – generally very large deals.
- Some companies may start using insurance to shift carbon risk from their balance sheets to maybe... yours?
- The president and founder of Genesis Today wants to improve America’s health, and thinks Wal-Mart can help.
- Switzerland's privacy watchdog is taking legal action to force Google to make changes to its Street View service.
Data is a real-time snapshot *Data is delayed at least 15 minutes